AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34882644 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics treatment
Number of subjects: 5938
Study 34882644 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural language processing and machine learning predictive model
Number of subjects: 5938
Study 34882831 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly selinexor, bortezomib, and dexamethasone
Number of subjects: 0
Study 34882831 — intervention group
Group type: COMPARATOR
Intervention: Standard twice-weekly bortezomib and dexamethasone
Number of subjects: 0
Study 34882989 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodynamic-guided management using the CardioMEMS HF System
Number of subjects: 100
Study 34884196 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein velocity (CRPv) measured as the difference of CRP 24 ± 8 h and CRP at hospital admission divided by the time (in h) that elapsed during the two examinations.
Number of subjects: 432
Study 34886825 — intervention group
Group type: EXPERIMENTAL
Intervention: hsPDA group
Number of subjects: 123
Study 34886825 — intervention group
Group type: COMPARATOR
Intervention: PDA group
Number of subjects: 123
Study 34886825 — intervention group
Group type: COMPARATOR
Intervention: noPDA group
Number of subjects: 123
Study 34886825 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal oxygenation
Number of subjects: 123
Study 34886885 — intervention group
Group type: EXPERIMENTAL
Intervention: TOFscan
Number of subjects: 35
Study 34886885 — intervention group
Group type: COMPARATOR
Intervention: TOF-Watch SX
Number of subjects: 35
Study 34886896 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 100
Study 34886896 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Examen
Number of subjects: 100
Study 34886896 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress inoculation training
Number of subjects: 100
Study 34886896 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 100
Study 34886910 — intervention group
Group type: EXPERIMENTAL
Intervention: Home therapy group (HT group) directed by surgeons at post-operative appointments
Number of subjects: 200
Study 34886910 — intervention group
Group type: COMPARATOR
Intervention: Outpatient rehabilitation by physical therapists (PT group)
Number of subjects: 200
Study 34886910 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PT and HT)
Number of subjects: 200
Study 34886909 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote nutrition monitoring intervention with tailored nutritional counseling before and after surgery at 2 and 4 weeks after hospital discharge. Participants recorded nutritional intake daily for 30 days, reviewed by registered dietitians.
Number of subjects: 19
Study 34887051 — intervention group
Group type: COMPARATOR
Intervention: Any PTX device
Number of subjects: 2456
Study 34887051 — intervention group
Group type: COMPARATOR
Intervention: PTX drug-coated balloon angioplasty
Number of subjects: 2456
Study 34887051 — intervention group
Group type: COMPARATOR
Intervention: PTX drug-eluting stent therapy
Number of subjects: 2456
Study 34887055 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal Echocardiography Guided Implantation
Number of subjects: 0
Study 34887055 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34887348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced CT (DCE-CT)
Number of subjects: 380
Study 34887348 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography/CT (PET/CT)
Number of subjects: 380
Study 34887348 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined DCE-CT and PET/CT
Number of subjects: 380
Study 34887348 — intervention group
Group type: COMPARATOR
Intervention: Cost-effectiveness analysis
Number of subjects: 380
Study 34887574 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-modulatory vaccine (IO102/IO103) combined with nivolumab
Number of subjects: 30
Study 34887772 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab added to moderate-intensity statin therapy
Number of subjects: 0
Study 34887772 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity statin therapy
Number of subjects: 0
Study 34888043 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Surgical and Injection of alcohol Treatment (COSIT), mean alcohol volume 72.0 mls, mean follow-up duration 16 months.
Number of subjects: 21
Study 34888099 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep duration (≤6 hours)
Number of subjects: 429
Study 34888099 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep duration (>6 hours)
Number of subjects: 429
Study 34888270 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to online games in preschool
Number of subjects: 0
Study 34888270 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to online games)
Number of subjects: 0
Study 34888330 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 0
Study 34888330 — intervention group
Group type: COMPARATOR
Intervention: Blood gases
Number of subjects: 0
Study 34888394 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological testing for SARS-CoV-2 antibodies
Number of subjects: 978
Study 34888394 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic region analysis
Number of subjects: 978
Study 34888394 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds ratio analysis for seropositivity
Number of subjects: 978
Study 34888394 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of serum neutralization titers
Number of subjects: 978
Study 34888394 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of antibody effectiveness against variants
Number of subjects: 978
Study 34888436 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail ultrasound (US) imaging
Number of subjects: 46
Study 34888436 — intervention group
Group type: EXPERIMENTAL
Intervention: DIP ultrasound (US) imaging
Number of subjects: 46
Study 34888518 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U/1 mL dilution of AbobotulinumtoxinA
Number of subjects: 321
Study 34888518 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U/2 mL dilution of AbobotulinumtoxinA
Number of subjects: 321
Study 34888735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (NO2) exposure
Number of subjects: 1292
Study 34888735 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine particulate matter (<2.5 µm) exposure
Number of subjects: 1292
Study 34888735 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse particulate matter (<10 µm) exposure
Number of subjects: 1292
Study 34888735 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure
Number of subjects: 1292
Study 34889102 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital ACEi/ARB use
Number of subjects: 1686
Study 34889102 — intervention group
Group type: COMPARATOR
Intervention: Control (no ACEi/ARB use)
Number of subjects: 1686
Study 34889108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation in patients with atrial fibrillation and heart failure
Number of subjects: 1303
Study 34889108 — intervention group
Group type: COMPARATOR
Intervention: Cryoballoon ablation in patients without heart failure
Number of subjects: 1303
Study 34889108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation in patients with heart failure
Number of subjects: 1303
Study 34889115 — intervention group
Group type: EXPERIMENTAL
Intervention: Early presenting patients (<6 hours)
Number of subjects: 118
Study 34889115 — intervention group
Group type: COMPARATOR
Intervention: Late presenting patients (6-24 hours)
Number of subjects: 118
Study 34889115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 118
Study 34889232 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (200 mg/day and 400 mg/day) and pembrolizumab (200 mg every 3 weeks)
Number of subjects: 22
Study 34889232 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate and pembrolizumab
Number of subjects: 22
Study 34889270 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions to reduce PM exposure
Number of subjects: 120
Study 34889270 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 34889382 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies for priapism
Number of subjects: 0
Study 34889382 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies for chronic leg ulcer disease
Number of subjects: 0
Study 34889382 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies for pulmonary hypertension
Number of subjects: 0
Study 34889384 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically modified T cells
Number of subjects: 0
Study 34889407 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapies for acute myeloid leukemia (AML)
Number of subjects: 0
Study 34889746 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-i Coach app alone
Number of subjects: 33
Study 34889746 — intervention group
Group type: COMPARATOR
Intervention: CBT-i Coach app with adjunctive physical activity (PA)
Number of subjects: 33
Study 34889746 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CBT-i Coach app alone and with PA)
Number of subjects: 33
Study 34889766 — intervention group
Group type: EXPERIMENTAL
Intervention: CONCERN Clinical Decision Support (CDS) system
Number of subjects: 0
Study 34889766 — intervention group
Group type: EXPERIMENTAL
Intervention: CONCERN CDS system
Number of subjects: 0
Study 34889776 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined clinical audits and low-dose, high-frequency (LDHF) in-service training for 6 months
Number of subjects: 600
Study 34889776 — intervention group
Group type: EXPERIMENTAL
Intervention: Refresher course in maternal neonatal and child health (MNCH) for 10 days plus LDHF training for 6 months
Number of subjects: 600
Study 34889776 — intervention group
Group type: COMPARATOR
Intervention: Standard MNCH refresher training delivered in a classroom setting
Number of subjects: 600
Study 34889775 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive intervention group (Fitbit use, daily HRQOL reports, personalized push notifications for 3 months)
Number of subjects: 3
Study 34889775 — intervention group
Group type: COMPARATOR
Intervention: Control group (Fitbit use, daily HRQOL reports for 3 months without personalized feedback)
Number of subjects: 3
Study 34889804 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia consisting of propofol induction and sevoflurane maintenance
Number of subjects: 71
Study 34890832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib (≥ 300 mg)
Number of subjects: 285
Study 34891077 — intervention group
Group type: EXPERIMENTAL
Intervention: mfERG
Number of subjects: 29
Study 34891077 — intervention group
Group type: EXPERIMENTAL
Intervention: OPs
Number of subjects: 29
Study 34891077 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (C)
Number of subjects: 29
Study 34891223 — intervention group
Group type: EXPERIMENTAL
Intervention: Betibeglogene autotemcel (beti-cel) gene therapy
Number of subjects: 23
Study 34893017 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth-rated alliance
Number of subjects: 65
Study 34893017 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-rated alliance
Number of subjects: 65
Study 34893017 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-rated alliance
Number of subjects: 65
Study 34893042 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 134
Study 34893042 — intervention group
Group type: COMPARATOR
Intervention: No suction drainage
Number of subjects: 134
Study 34893522 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal CO₂ removal (ECCO₂R); mean time on ECCO₂R was 5.4 days.
Number of subjects: 51
Study 34893522 — intervention group
Group type: COMPARATOR
Intervention: Control group (Invasive mechanical ventilation - IMV); mean time on IMV was 27 days.
Number of subjects: 51
Study 34893522 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCO₂R; 4 patients required IMV, 3 after ECCO₂R weaning.
Number of subjects: 51
Study 34893522 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCO₂R; mean ICU stay was 18 days.
Number of subjects: 51
Study 34893522 — intervention group
Group type: COMPARATOR
Intervention: Control group (IMV); mean ICU stay was 30 days.
Number of subjects: 51
Study 34893524 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enadenotucirev plus paclitaxel
Number of subjects: 38
Study 34893524 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal enadenotucirev monotherapy
Number of subjects: 38
Study 34893603 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR19 T-cells
Number of subjects: 54
Study 34893771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel BCMA-targeted CAR-T cell therapy
Number of subjects: 1
Study 34893775 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 700
Study 34893775 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 700
Study 34893942 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine (150 µg/kg every 3 weeks for 2 cycles; 75 µg/kg Q3W thereafter)
Number of subjects: 328
Study 34893945 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Number of subjects: 14
Study 34893952 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanning
Number of subjects: 0
Study 34893952 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 0
Study 34893952 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 34893952 — intervention group
Group type: EXPERIMENTAL
Intervention: All procedures and treatments
Number of subjects: 0
Study 34893952 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 34894221 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine (3 priming doses)
Number of subjects: 0
Study 34894221 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine (annual booster dose)
Number of subjects: 0
Study 34894221 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine (2nd booster dose)
Number of subjects: 0
Study 34894221 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine (post-vaccination antibody response)
Number of subjects: 0
Study 34894235 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine (CoronaVac), two doses administered at D0 and D28.
Number of subjects: 51
Study 34894235 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF monotherapy in SSc patients.
Number of subjects: 51
Study 34894235 — intervention group
Group type: COMPARATOR
Intervention: Control group (153 individuals without SSc).
Number of subjects: 51
Study 34894307 — intervention group
Group type: EXPERIMENTAL
Intervention: adjunctive brexpiprazole 1-3 mg/day
Number of subjects: 105
Study 34894329 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi with SGLT2i
Number of subjects: 1631
Study 34894329 — intervention group
Group type: COMPARATOR
Intervention: iGlarLixi without SGLT2i
Number of subjects: 1631
Study 34894328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 36
Study 34894328 — intervention group
Group type: COMPARATOR
Intervention: Control group (22 subjects)
Number of subjects: 36
Study 34894378 — intervention group
Group type: EXPERIMENTAL
Intervention: LevelMind@JC service
Number of subjects: 1300
Study 34894378 — intervention group
Group type: COMPARATOR
Intervention: Generic youth services
Number of subjects: 1300
Study 34894681 — intervention group
Group type: EXPERIMENTAL
Intervention: JNK inhibitors with increased JNK1 bias, specifically a novel series of 2,4-dialkylamino-pyrimidine-5-carboxamides
Number of subjects: 0
Study 34894681 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dosing of optimized JNK inhibitors
Number of subjects: 0
Study 34895133 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP antibodies treatment for 3 months
Number of subjects: 22
Study 34895181 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg over 12 weeks
Number of subjects: 122
Study 34895190 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment or Open Reduction Internal Fixation (ORIF)
Number of subjects: 55
Study 34895190 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 55
Study 34895196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (CIrCLE of Life Initiative)
Number of subjects: 537
Study 34895259 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stromal cells (10, 40, and 100 million cells per knee)
Number of subjects: 0
Study 34895259 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of autologous cells
Number of subjects: 0
Study 34895264 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ovarian stimulation regimen of 150 micrograms corifollitropin alfa (Elonva®) followed by 200 IU follitropin beta (Puregon®) per day
Number of subjects: 192
Study 34895272 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV vaccine and monoclonal antibody trials
Number of subjects: 1934
Study 34895272 — intervention group
Group type: EXPERIMENTAL
Intervention: Current recruitment approach
Number of subjects: 1934
Study 34895272 — intervention group
Group type: EXPERIMENTAL
Intervention: Current trials
Number of subjects: 1934
Study 34895290 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (2 g/kg over 12-24 h with a maximum dose of 60 g) + aspirin (30 mg/kg/d) + prednisolone (2 mg/kg/d with a maximum dose of 60 mg tapered over 15 days after normalization of C-reactive protein concentration)
Number of subjects: 0
Study 34895290 — intervention group
Group type: COMPARATOR
Intervention: IVIG (2 g/kg over 12-24 h with a maximum dose of 60 g) + aspirin (30 mg/kg/d)
Number of subjects: 0
Study 34895296 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 0
Study 34895296 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 0
Study 34895314 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental vestibular adaptation training device
Number of subjects: 0
Study 34895314 — intervention group
Group type: COMPARATOR
Intervention: Traditional vestibular rehabilitation
Number of subjects: 0
Study 34895320 — intervention group
Group type: EXPERIMENTAL
Intervention: CT angiography (CTA)
Number of subjects: 382
Study 34895320 — intervention group
Group type: COMPARATOR
Intervention: Non-CTA
Number of subjects: 382
Study 34895316 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal assessment of sarcopenia and its underlying mechanisms in chronic inflammatory diseases.
Number of subjects: 220
Study 34895316 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group) for comparison.
Number of subjects: 220
Study 34895347 — intervention group
Group type: EXPERIMENTAL
Intervention: Leader-perceived Implementation Citizenship Behavior (ICB)
Number of subjects: 194
Study 34895347 — intervention group
Group type: EXPERIMENTAL
Intervention: Subscale of keeping informed
Number of subjects: 194
Study 34895347 — intervention group
Group type: EXPERIMENTAL
Intervention: Practitioner-perceived implementation leadership
Number of subjects: 194
Study 34895351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition knowledge index (NKI) scores for females
Number of subjects: 400
Study 34895351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition knowledge index (NKI) scores for males
Number of subjects: 400
Study 34895351 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported ability to seek and verify nutrition information
Number of subjects: 400
Study 34895351 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with higher NKI scores
Number of subjects: 400
Study 34895430 — intervention group
Group type: EXPERIMENTAL
Intervention: Clogs
Number of subjects: 153
Study 34895430 — intervention group
Group type: EXPERIMENTAL
Intervention: Sneakers
Number of subjects: 153
Study 34895430 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandals
Number of subjects: 153
Study 34895430 — intervention group
Group type: COMPARATOR
Intervention: Specialty preference
Number of subjects: 153
Study 34895430 — intervention group
Group type: COMPARATOR
Intervention: Seniority preference
Number of subjects: 153
Study 34895430 — intervention group
Group type: COMPARATOR
Intervention: Footwear condition
Number of subjects: 153
Study 34895430 — intervention group
Group type: COMPARATOR
Intervention: Gender preference
Number of subjects: 153
Study 34895487 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel
Number of subjects: 148
Study 34895750 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Anticoagulants (OACs)
Number of subjects: 9135
Study 34895750 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 9135
Study 34895750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-K-Antagonists (VKAs)
Number of subjects: 9135
Study 34895798 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational messages sent via SMS for 21 days (n=41)
Number of subjects: 87
Study 34895798 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=46)
Number of subjects: 87
Study 34895804 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with T2D
Number of subjects: 3163
Study 34895804 — intervention group
Group type: COMPARATOR
Intervention: Males with T2D
Number of subjects: 3163
Study 34895986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-associated neodifferentiation (TAND) concept
Number of subjects: 0
Study 34895986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-associated fibroblasts (CAFs)
Number of subjects: 0
Study 34896005 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage two-layer continuous closure
Number of subjects: 11
Study 34896295 — intervention group
Group type: EXPERIMENTAL
Intervention: Notification of clinicians about patient overdose via a letter.
Number of subjects: 0
Study 34896295 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study 34896356 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary telemedicine (IDC-TM)
Number of subjects: 124